Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06627244 · ClinicalTrials.gov registry record · Phase 2
Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma
A Phase 2 study of Metastatic Uveal Melanoma and Metastatic Uveal Melanoma in the Liver, sponsored by University of Miami.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06627244 is a Phase 2 study of Metastatic Uveal Melanoma and Metastatic Uveal Melanoma in the Liver that is actively recruiting participants, run by University of Miami. The registered enrollment target is 30 participants, below the 130-participant average among 14 other Metastatic Uveal Melanoma trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06627244, a Phase 2 study of Metastatic Uveal Melanoma and Metastatic Uveal Melanoma in the Liver, is actively recruiting participants, sponsored by University of Miami.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the effects (good and bad) that Tebentafusp in combination with Yttrium-90 (Y-90) radioembolization has on patients with metastatic uveal melanoma that has spread to the liver.
Conditions Studied
Interventions
- RADIATION TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization
- DRUG Tebentafusp
Study Locations (1)
Florida
- University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-02-14 |
| Est. Completion | 2031-02-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06627244
The ClinicalTrials.gov registry entry for NCT06627244 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 130-participant average among 14 other Metastatic Uveal Melanoma trials with a reported enrollment target (77% lower). The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Uveal Melanoma appearing as the primary indexed condition, and to 2 interventions - of which TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization is the first listed.
NCT06627244 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06627244 about?
NCT06627244 is a clinical study titled "Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma". The purpose of this study is to determine the effects (good and bad) that Tebentafusp in combination with Yttrium-90 (Y-90) radioembolization has on patients with metastatic uveal melanoma that has spread to the liver.
What is the current status of trial NCT06627244?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2025-02-14. Estimated completion is 2031-02-17.
What conditions does trial NCT06627244 study?
This clinical trial studies the following conditions: Metastatic Uveal Melanoma, Metastatic Uveal Melanoma in the Liver.
What interventions are being tested in trial NCT06627244?
The interventions under investigation include: TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization (RADIATION), Tebentafusp (DRUG).
Who is sponsoring clinical trial NCT06627244?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06627244 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Uveal Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases
ACTIVE NOT RECRUITING · Phase 2
-
Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Metastatic Uveal Melanoma
All registered trials for this condition
Metastatic Uveal Melanoma in the Liver
All registered trials for this condition
Florida
All trials with a study site in Florida
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.